3 / 33
Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-
label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577–589.
Wu, Y., Zhou, C., Hu, C., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J., Lee, K., Xu, C., Massey, D., Kim, M., Shi, Y. and Geater, S. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian
patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The Lancet Oncology. 2014;15(2):213-222.dels
FIRST GENERATION
Erlotinib
Gefitinib
Reversible
Sensitive mut
SECOND GENERATION
Afatinib
Dacomitinib
Irreversible-covalent
Sensitive mut
THIRD GENERATION
Osimertinib
Irreversible-specific
Sensitive and resistant
T790M mut
EGFR Tyrosine Kinase inhibitors
In red approved for treatment of EGFRm NSCLC
TKIs Standard of care in EGFR mutant patients